FundamentalVR Announces Expansion into Endovascular Surgery

FundamentalVR, global pioneers in immersive VR surgical skills training and performance data, today announced the addition of endovascular surgery to its expanding suite of haptic surgical training procedures.

Alongside this capability for new endovascular procedures, the company also offers CollaborationVR, a personalized virtual space with unlimited capacity specifically designed for healthcare professionals to meet and accelerate procedural and product adoption together.

A leading player in surgical education, FundamentalVR’s simulations are delivered through its Fundamental Surgery platform. The platform is powered by the company’s unique HapticVRTM technology which mimics the physical cues of surgical actions, tools, and tissue textures felt in real-life surgery. FundamentalVR provides a gold standard of immersive surgical training using these technologies, and their immersive learning platform has already delivered success for medical device and pharmaceutical companies across orthopedics, general surgery, robotics, and ophthalmology.

In creating high-fidelity simulations for a variety of specialisms, the platform is enabling medical institutions and life science organizations to remotely train personnel en masse without having to compromise on quality. By leveraging CollaborationVR, HapticVR and other features on the Fundamental Surgery platform, FundamentalVR ensures that personnel are given the dynamic environment needed to explore patient cases, anatomy, devices, procedures and more to achieve their learning goals. Including implementing virtual products, which customers can build as direct replicas of real-life devices.

With such credentials, the Fundamental Surgery platform is well equipped to simulate Image-Guided Interventional procedures all with full haptic feedback and high-resolution graphics. Examples include Acute Ischemic Stroke, EVAR, Cardiac Rhythm Management, Coronary Interventions, and Carotid Interventions.

“Our solutions can be adapted to multiple procedures and tools and remain the only medical VR education platform accredited by the Royal College of Surgeons” says Richard Vincent, co-founder and CEO of FundamentalVR.

By creating low-cost, “pre-human” immersive simulations, FundamentalVR dramatically accelerates the transfer of skills and the adoption of new procedures, tools, and equipment at scale and more economically than ever before.

Already deployed across the globe for use by medical device makers and centers of excellence, Fundamental Surgery’s equipment-agnostic nature allows it to work with a range of off-the-shelf hardware. Its notable benefits to medical educators and life science companies include:

  • Blended Immersive Technology: Offers various modalities that fit each stage of the learning pathway to provide unparalleled flexibility. Depending on each business use case, they can be used individually or together, ultimately reducing time and cost while increasing capability and confidence.
  • Enhanced market penetration: Enables life science companies to experiment and conduct trials more conveniently anywhere, anytime, with surgeons on new techniques, therapies, and products, reducing barriers to bringing new tools to market.
  • Multiuser platform using CollaborationVR: Allows for an unlimited number of users to meet, interact, and teach within virtual classrooms and operating rooms. Join, monitor, and access remotely from anywhere in the world.
  • Scalability: The low-cost platform is compatible with off-the-shelf hardware and can be transported easily. It enables a scalable software-based platform that is future-proof, creating a robust infrastructure to ensure the investment does not date as hardware improves.
  • Data and Cloud-Based Analytics: Every user interaction and decision is measured and recorded in detail, with metrics including economy of movement, 3D spatial awareness, surgical gaze, respect for tissue, and human factors such as dealing with adverse events and complications.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.